675576-98-4

Basic information

• Product Name: 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone
• Synonyms: 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone;Nutlin 3a;Nutlin-3a (chiral);2-Piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-;4-[[(4S,5R)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone Nutlin 3a;Nutlin 3a 4-[[(4S,5R)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone;4-[[(4S,5R)-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]carbonyl]piperazin-2-one;4-[[(4S,5R)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-
• CAS NO: 675576-98-4
• Molecular Formula: C30H30Cl2N4O4
• Molecular Weight: 581.497
• Product Categories: Inhibitors
• Mol File: 675576-98-4.mol
• Article Data: 8

Chemical Properties

• Appearance: white to beige/
• Density: 1.36
• Storage Temp.: ?20°C
• Solubility: DMSO: soluble5mg/mL, clear
• PKA: 14.35±0.20(Predicted)
• CAS DataBase Reference: 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone(675576-98-4)
• EPA Substance Registry System: 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone(675576-98-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 675576-98-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 675576-98-4 differently. You can refer to the following data:
1. (ndash)-Nutlin-3 is an inhibitor of p-53-MDM2 interaction. Anti-cancer agent.
2. Nutlin-3a has been used as a tumor suppressor p53(TP53) stabilizer and as an inhibitor of the mouse double minute 2 homolog (MDM2)–p53 interaction.

Biological Activity

nutlin-3 is a small-molecule inhibitor of mdm2 (mouse double minute 2) with ic50 value of 0.09μm [1].nutlin-3 binds mdm2 in the tp53-bindingpocket, thereby interfering with mdm2-directed tp53 degradation. this has been shown to cause cell cycle arrest, growth inhibitionand apoptosis in both solid tumors and lymphoid neoplasms.in mantle cell lymphoma(mcl), it is reported that nutlin-3 can inhibit cell growth and activate apoptosis in bothwt-tp53(ic50 of 1 to 10μm) and mt-tp53(ic50 of 22.5μm) cells [2].nutlin-3 can also effectcell cycle in gastric cancer cell lines. it induces g1 arrest inmkn-45 and snu-1 cell lines. in vitro assay shows nutlin-3can enhance the antitumoreffects of conventional chemotherapeutic agents in several gastric cancer cell lines. and in in vivo assay, nutlin-3 significantly inhibits the growth of xenograft tumors [3].

Biochem/physiol Actions

Nutlin-3a is a potent nongenotoxic drug. It acts as a tumor suppressor p53 (TP53) activator and stabilizer.

references

[1] lyubomir t.vassilev et al. in vivo activation of the p53 pathway by small-molecule antagonists of mdm2.science.2004, 303: 844-848.[2] yoko tabe, denise sebasigari, linhua jin, et al.mdm2 antagonist nutlin-3 displays antiproliferative andproapoptotic activity in mantle cell lymphoma. clin cancer res. 2009, 15:933-942.[3] shinji endo,kenji yamato,sachiko hirai,toshikazu moriwaki,kuniaki fukuda,hideo suzuki,masato abei,ichiro nakagawa and ichinosukehyodo.potent in vitro and in vivo antitumor effects ofmdm2 inhibitor nutlin-3 in gastric cancer cells.cancer science. 2011, 102 (3): 605-613.

Upstream product

• 86212-34-2 (1R,2S)-1,2-bis(4-chlorophenyl)ethane-1,2-diamine 
• 3848-36-0 4-chlorobenzaldoxime 
• 774225-25-1 N-(tert-butoxycarbonyl)-α-(phenylsulfonyl)-4-chlorobenzylamine 
• 104-88-1 4-chlorobenzaldehyde 
• 106-43-4 para-chlorotoluene 
• 622-95-7 4-chlorobenzyl bromide 
• 2237-36-7 4-methoxysalicylic acid 
• 1353891-93-6 N-((1R,2S)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carboxamide 
• 1353891-90-3 tert-butyl (1R,2S)-1,2-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethylcarbamate 
• 1353891-52-7 tert-butyl ((1R,2S)-1,2-bis(4-chlorophenyl)-2-nitroethyl)carbamate 
• 1353891-92-5 N-((1S,2R)-2-amino-1,2-bis(4-chlorophenyl)ethyl)-2-isopropoxy-4-methoxybenzamide 
• 1353891-88-9 tert-butyl ((1R,2S)-2-amino-1,2-bis(4-chlorophenyl)ethyl)carbamate 
• 1353891-99-2 isopropyl 2-isopropoxy-4-methoxybenzoate 
• 779342-75-5 tert-butyl 4-chlorobenzylidenecarbamate 

Relevant articles and documents

Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use

This invention provides a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by selective cry

Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis -stilbene diamines: A platform for the preparation of single-enantiomer cis -imidazolines for protein-protein inhibition

The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein-protein interaction between p53 and MDM2, thereby inducing apoptosis in cancer cells, raised considerable interest in this scaffold over the past decade. Initial routes to these small molecules (i.e., Nutlin-3) provided only the racemic form, with enantiomers being enriched by chromatographic separation using high-pressure liquid chromatography (HPLC) and a chiral stationary phase. Reported here is the first application of an enantioselective aza-Henry approach to nonsymmetric cis-stilbene diamines and cis-imidazolines. Two novel mono(amidine) organocatalysts (MAM) were discovered to provide high levels of enantioselection (>95% ee) across a broad range of substrate combinations. Furthermore, the versatility of the aza-Henry strategy for preparing nonsymmetric cis-imidazolines is illustrated by a comparison of the roles of aryl nitromethane and aryl aldimine in the key step, which revealed unique substrate electronic effects providing direction for aza-Henry substrate-catalyst matching. This method was used to prepare highly substituted cis-4,5-diaryl imidazolines that project unique aromatic rings, and these were evaluated for MDM2-p53 inhibition in a fluorescence polarization assay. The diversification of access to cis-stilbene diamine-derived imidazolines provided by this platform should streamline their further development as chemical tools for disrupting protein-protein interactions.

Preparation of (-)-nutlin-3 using enantioselective organocatalysis at decagram scale

Chiral nonracemic cis-4,5-bis(aryl)imidazolines have emerged as a powerful platform for the development of cancer chemotherapeutics, stimulated by the Hoffmann-La Roche discovery that Nutlin-3 can restore apoptosis in cells with wild-type p53. The lack of efficient methods for the enantioselective synthesis of cis-imidazolines, however, has limited their more general use. Our disclosure of the first enantioselective synthesis of (-)-Nutlin-3 provided a basis to prepare larger amounts of this tool used widely in cancer biology. Key to the decagram-scale synthesis described here was the discovery of a novel bis(amidine) organocatalyst that provides high enantioselectivity at warmer reaction temperature (-20 C) and low catalyst loadings. Further refinements to the procedure led to the synthesis of (-)-Nutlin-3 in a 17 g batch and elimination of all but three chromatographic purifications.